Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ionis Pharmaceuticals (IONS) -- Ignore unavailable to you. Want to Upgrade?

To: james who wrote (1373)	12/5/1997 12:03:00 PM
From: Pseudo Biologist	Read Replies (1) \| Respond to of 4676

James, I do not know anything about NGF. I do know Genentech has been building a Bioorganic Chemistry group for some time; a lot of what they have published has dealt with small-molecule RGD mimetics, but they have also published on Ras farnesyl transferase (a cancer target) inhibitors (see for example, ncbi.nlm.nih.gov ) I have not checked the clinical status of this work. They also have an interest and done some crucial work in the VEGF area. I think they have a humanized MAb in early clinical for this; they may be doing small molecule work on this as well (my wild guess - no facts). My comment is based in two pieces of information, (1) as said above, buildup of organic chemistry + protein crystallography + computational chemistry capabilities and (2) current cancer focus, although using MAbs, with IDEC's Rituxan, anti-HER2, anti-VEGF, ...? Put (1) and (2) together and I see it reasonable to guess that "small molecules are coming too" when? who knows. PB